charles river

J.P. Morgan 44th Annual Healthcare Conference

January 13, 2026

James C. Foster

Chair, President & Chief Executive Officer

Safe Harbor Statement

Caution Concerning Forward-Looking Statements. This presentation includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as “anticipate,” “believe,” “expect,” “intend,” “will,” “may,” “estimate,” “plan,” “outlook,” and “project” and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These statements also include statements about: the proposed acquisitions of K.F. (Cambodia) Ltd. and PathoQuest SAS; expectations regarding the terms and the timing of the closing of the proposed acquisitions of K.F. and PathoQuest; expectations with respect to the impact of the proposed acquisitions of K.F. and PathoQuest on the Company, its product and service offerings, supply chain and requirements, NHP sourcing, methodologies to reduce animal use, client perception, revenue, including operating margin and related cost savings, third-party revenue, revenue growth rates, earnings per share, and 2026 or 2027 GAAP or non-GAAP financial results; the Company’s expectations concerning projected future financial and operating performance, including with respect to revenue and booking activity and related financial metrics; the Company's commitment to, and ability to create long-term value for shareholders and to successfully execute on the strategies described herein; client demand, including trends and the future demand for the Company’s products and services; the impact of foreign exchange; the impact of timing of NHP shipments; the impact of CRADL occupancy rates; our expectations with respect to annualized cost savings; changes and uncertainties in the global economy and financial markets; our future financial performance and drivers thereof (including, without limitation, revenue and revenue growth rates, operating income and margin, earnings per share, capital expenditures, operating and free cash flow, net interest expense, effective tax rate, foreign exchange rates, corporate expenses, and leverage ratios) whether reported, constant currency, organic, and/or factoring acquisitions, with respect to Charles River as a whole and/or any of our reporting or operating segments or business units; our expectations with respect to the impact of external interest rate fluctuations; our annual guidance and longer-term targets, including the assumptions that form the basis for such guidance and targets; client demand, including the impact of demand trends and KPIs, and our ability to increase client interest and the future demand for drug discovery, development, and contract development and manufacturing organization (“CDMO”) and cell and gene therapy (“C&GT”) products and services; our intentions to expand our businesses, including our investments in our portfolio; the timing of business developments, including timing of scientific enhancements to support such developments and our expectations with respect to alternative methodologies; our ability to fund our operations for the foreseeable future; the impact of foreign exchange; our expectations regarding stock repurchases and debt repayment; the development and performance of our services and products, including expectations with respect to reducing timelines; expectations with respect to pricing of our products and services; market and industry conditions, including industry consolidation and the Company’s share of any market it participates in; outsourcing of services and identification of spending trends by our clients and funding available to them; the potential outcome of, and impact to, our business and financial operations due to litigation and legal proceedings and tax law changes; our business strategy, including with respect to capital deployment and leverage; our success in identifying, consummating, and integrating, and the impact of, our acquisitions, on the Company, our service offerings, client perception, strategic relationships, revenue, revenue growth rates, earnings, and synergies, including client overlap; our expectations regarding the financial performance of the companies we have acquired (including the impact of specific actions intended to cause related improvements, particularly with respect to our CDMO business); our strategic agreements with our clients and opportunities for future similar arrangements; the timing of and our ability to obtain new clients in targeted market segments and/or to predict which client segments will be future growth drivers; the impact of our investments in specified business lines, products, sites and geographies; and Charles River’s future performance as otherwise delineated in our forward-looking guidance.

Forward-looking statements are based on Charles River’s current expectations and beliefs, and involve a number of risks and uncertainties that are difficult to predict and that could cause actual results to differ materially from those stated or implied by the forward- looking statements. Those risks and uncertainties include, but are not limited to:; the impact of the events described herein, including the ability to successfully complete the proposed acquisitions of K.F. and PathoQuest; the ability to successfully integrate K.F. and PathoQuest, and risks and uncertainties associated with K.F.’s and PathoQuest’s businesses; changes and uncertainties in the global economy and financial markets, including any changes in business, political, or economic conditions; the ability to successfully integrate businesses we acquire; the timing and magnitude of our share repurchases; negative trends in research and development spending, negative trends in the level of outsourced services, or other cost reduction actions by our clients; the ability to convert backlog to revenue; special interest groups; contaminations; industry and market trends and conditions; new displacement technologies; U.S. Department of Agriculture (“USDA”) and Food and Drug Administration (“FDA”) regulations; changes in law; continued availability of products and supplies; loss of key personnel; interest rate and foreign currency exchange rate fluctuations; changes in tax regulation and laws; changes in generally accepted accounting principles; and any changes in business, political, or economic conditions due to the threat of future terrorist activity in the U.S. and other parts of the world, and related U.S. military action overseas. A further description of these risks, uncertainties, and other matters can be found in the Risk Factors detailed in Charles River's Annual Report on Form 10-K as filed on February 19, 2025, as well as other filings we make with the Securities and Exchange Commission. Because forward- looking statements involve risks and uncertainties, actual results and events may differ materially from results and events currently expected by Charles River, and Charles River assumes no obligation and expressly disclaims any duty to update information contained in this presentation except as required by law.

Regulation G

This presentation includes discussion of non-GAAP financial measures. We believe that the inclusion of these non-GAAP financial measures provides useful information to allow investors to gain a meaningful understanding of our core operating results and future prospects, without the effect of often one-time charges, consistent with the manner in which management measures and forecasts the Company’s performance. The non-GAAP financial measures included in this presentation are not meant to be considered superior to or a substitute for results of operations prepared in accordance with GAAP. The company intends to continue to assess the potential value of reporting non-GAAP results consistent with applicable rules and regulations. In accordance with Regulation G, you can find the comparable GAAP measures and reconciliations to those GAAP measures on our website at ir.criver.com.

Quiet Period Disclaimer

The Company is presently in quiet period pending the release of its fourth-quarter and full-year 2025 financial results and 2026 guidance in February 2026. As a result, the Company will not comment on its financial performance for the fourth quarter of 2025.

The Scientific Partner of Choice to Accelerate Biomedical Research and Therapeutic Innovation

Working with clients from discovery and early-stage development through the safe manufacture of life-saving therapies

Leading, Global, Non-Clinical Drug Development Partner with a Mission to Create Healthier Lives

Global Scale

~20,000
Global employees

~2,500
Scientific professionals with advanced degrees

~70%
Revenue from biopharma industry

~120*
Locations in

~20
Countries

Attractive Market Position

#1
Position in Research Models, Safety Assessment & Microbial Solutions

Supported
>80%
of FDA-approved novel drugs over last five years (2021-25)

~$25B
addressable market opportunity provides long runaway for future growth





* Includes certain sites being consolidated as part of Company's footprint rationalization efforts.
** Other client segment includes agricultural & industrial chemical, CRO, animal health, life science, CDMO, consumer product, and medical device companies.
LTM 2025 revenue based on LTM (last twelve months) financial information through September 27, 2025.

charles river

Proven and Resilient Financial Performance

Revenue

($ in millions)



Operating & Free Cash Flow

($ in millions)



Non-GAAP Operating Income $/Margin %**

($ in millions, except margin amounts)



Non-GAAP EPS**



See ir.criver.com for reconciliations of GAAP to non-GAAP results.

** LTM 2025 revenue based on LTM (last twelve months) financial information through September 27, 2025*

*** **GAAP Operating Income $/Margin %:** 2021: $590M / 16.7%; 2022: $651M / 16.4%; 2023: $617M / 14.9%; 2024: $227M / 5.6%*

__GAAP EPS:__ 2021: $7.60; 2022: $9.48; 2023: $9.22; 2024: $0.20 .

charles river

Unique, Scientifically Differentiated Portfolio

Research Models and Services (RMS)

Global leader in the production of the most widely used small research models and associated services

Foundational tools that enable clients to discover new molecules

(21% of LTM Sept. 2025 annual revenue)

Discovery and Safety Assessment (DSA)

Largest, global partner for outsourced drug discovery, non-clinical development, and regulated safety testing services

Enabling preclinical success and efficiently advancing ideas into the clinic

(60% of LTM Sept. 2025 annual revenue)

Manufacturing Solutions

Full-service process development, clinical-to-commercial manufacturing, and quality-control testing products and services

Ensuring the quality and safety of manufacturing activities and commercial therapies

(19% of LTM Sept. 2025 annual revenue)



Research & Development Continuum

LTM 2025 revenue based on LTM (last twelve months) financial information through September 27, 2025.
Note: DSA segment provides certain services to support clinical development, including clinical bioanalysis/lab sciences. However, the Company does not conduct human clinical trials.

charles river

RMS Segment

Foundational tools for the discovery of new molecules

Research Products
Production and distribution of the most widely used small research models, as well as large models and cellular products

Services
Flexible solutions that support our clients' use of models and the screening of drug candidates

- **Global footprint** ensures proximity to major biohubs
- Consistent, high-quality source of small research models **enhances synergies with DSA business**
- **Enhanced digital enterprise** improves efficiency and client experience
- Creative strategies, including **CRADL™,** to attract emerging biopharma clients at earlier stages
- **GEMS** services help clients navigate the increasing complexity of drug research

#1 Global RMS Position



>140
of the most widely used research model strains

Note: CRL market share data based on management estimates and publicly available information.

charles river

DSA Segment

Drug discovery research, development, and regulatory-required safety testing of potential new drugs

Discovery Services

Single source of services for discovering and characterizing novel drug candidates for preclinical development

Safety Assessment (SA)

Full suite of safety studies required for regulatory submission on a global basis across all therapeutic areas

- Early discovery, *in vivo*, and *in vitro* capabilities
  - Expertise in most major therapeutic areas, with a focus on **oncology** and **CNS**
- **Broad capabilities** across small and large molecule, antibody, and C&GT
- Expertise in **integrated programs**
  - Ability to engage with clients at any stage of their discovery or early-stage development programs
- **Global leader** in both non-regulated and regulated (GLP) outsourced SA services
- **Broad scientific capabilities**
  - General and specialty toxicology, **lab sciences and bioanalysis**, pathology, safety pharmacology, drug metabolism, and pharmacokinetics (DMPK) services
  - **Broadest specialty toxicology offering** from inhalation and infusion to developmental and reproductive toxicology

Outsourced SA Market Sector *

~1,500

IND programs supported by CRL annually

Note: CRL market share data based on management estimates and publicly available information.
* Safety Assessment market sector size definition does not reflect larger bioanalysis market opportunity, particularly related to clinical phases.

charles river

Manufacturing Solutions Segment

Safe production and release of manufactured products

Microbial Solutions
Rapid, efficient testing platform for microbial detection and identification of sterile and non-sterile applications

- Leading global provider of **quality-control (QC) testing** products and services
  - **FDA-mandated** lot release testing for sterile biopharmaceutical products
- **Market-leading platforms**
  - **Endosafe®** endotoxin detection
  - **Accugenix®** microbial identification and strain typing
  - **Celsis®** rapid microbial detection

Biologics Testing
Process development and quality-control testing to support the manufacture of biologics

- **Premier global partner** in navigating the complex pathway to biologic effectiveness
  - Supports developers and manufacturers with their **testing, characterization, and cell bank manufacturing** needs
  - **Testing and assay development** throughout drug development, clinical, and commercial manufacturing

C&GT CDMO
Scientific partner for C&GT development, testing, and manufacturing

- Solutions across **all major CDMO platforms for C&GT**
  - **Primary expertise in gene-modified cell therapy** with growing capabilities in gene therapy, including plasma DNA and viral vectors
- Complementary to CRL's **Biologics Testing** capabilities
  - **Integrated value chain** to provide **analytical testing** capabilities with the production of advanced therapies

Biologics Industry Pipeline By Subsegment



~65%

of Microbial Solutions revenue from reagents/consumables, creating a recurring revenue stream

charles river

CRL Positioned for Long-Term Value Creation

Unparalleled leader in preclinical drug development with deep analytical testing capabilities across R&D continuum

Attractive long-term growth opportunity expected to re-emerge once biopharmaceutical spending rebounds

- Believe **global biopharma** demand trends have **bottomed** after a period of restructuring and pipeline reprioritization and began to **slightly improve** in 2025
- **Positive signs for small and mid-sized biotech demand in 2H25** commensurate with improved biotech funding

Broad and scientifically differentiated portfolio drives leading market position

- Committed to continuing to **expand market leadership** through enhancing scientific expertise, analytical testing capabilities, and global reach, including through M&A

Indispensable partner to biopharmaceutical clients from basic research through drug development and commercial approval

- Focused on continuing to **grow wallet share** of clients' R&D spending across our portfolio

Best positioned to lead the industry through evolving landscape driven by scientific innovation, including NAMs

Disciplined financial management and execution

- Strong free cash flow generation enables significant investments in future growth
- Disciplined cost management and focus on operating efficiency with a goal to drive **meaningful operating margin expansion** as client demand reinvigorates

Recent Actions to Enhance Long-Term Shareholder Value

Implementing Actions from Board's Strategic Review in 2025

1. Strengthening **scientific portfolio** within core markets (including **M&A** and partnerships)
2. **Divesting** underperforming or non-core assets representing **~7%** of 2025E revenue
3. Maximizing financial performance
4. Maintaining **disciplined** approach to **capital deployment**

Significant Board Refreshment in 2025

Four new Board members joined in May 2025

- Reduced avg. Board tenure to ~6 years, from ~12 years
- Also established a New Approach Methodologies and Science (**NAMS**) **Committee** of the Board

Protecting operating margin during current demand environment

Expect to deliver **~$295M** in cumulative, **annualized cost savings** by 2026

- In November 2025, announced an additional ~$70M in cost savings through initiatives to drive greater operating efficiency

Balanced Approach to Capital Deployment

Optimizing balance between strategic acquisitions, stock repurchases, debt repayment, and other uses of capital

- Refreshed **stock repurchase authorization** with new **$1B** approved by Board in Oct. 2025

M&A Focusing on Core Market Sectors

Recent announcement of planned K.F. (Cambodia) and PathoQuest acquisitions supports future growth

- **K.F.**: Signed agreement to acquire **K.F. (Cambodia) Ltd. (Cambodian supplier of high-quality NHPs)** for **~$510M** to further strengthen and secure the DSA supply chain; Transaction expected to close early in 1Q26
  - Transaction will also generate **meaningful operating margin improvement through significant cost savings on NHP supply**
    - Expected to result in **non-GAAP EPS accretion** of **~$0.25** in 2026 and **~$0.60** in 2027
  - Acquisition enables greater oversight and operational control of a key supply source, including continued focus on biosecurity, regulatory compliance, and audit practices
  - CRL has been a long-term supply partner of K.F., which supplied CRL with **slightly above 30% of the globally sourced NHPs for use in its DSA operations over the last two years (2024-2025)**
    - Including **Noveprim**, transaction will enable **CRL to own and internally source most of its future, annual NHP supply requirements** for the DSA segment
- **PathoQuest**: Exercised option to acquire **remaining 79%** equity stake of **PathoQuest SAS (Paris-based provider of next-generation sequencing (NGS) solutions)** for **~$60M**; Transaction expected to close by end of 1Q26
  - CRL partner since 2016 and will **strengthen our Biologics Testing capabilities** by adding rapid, *in vitro* GMP and non-GMP testing solutions for manufacturing quality-control testing
  - PathoQuest's innovative NGS approach supports CRL's Alternative Methods Advancement Project (AMAP) initiative by **utilizing new approach methodologies (NAMs) to replace animal use in viral safety workflows**
  - PathoQuest expected to generate **$15-$20M in 2026 annual revenue** and transaction will not have material impact on GAAP or non-GAAP financial results in 2026 or 2027

Balanced Approach to Capital Allocation

Optimizing capital deployment to drive long-term growth and enhance value creation

CAPITAL EXPENDITURES

Reduced capital needs to align with current demand environment

5.1% of LTM Revenue*
(vs. peak of 8.2% of 2022 Revenue)

DEBT REPAYMENT

Maintain **reasonable leverage** levels

Gross & net leverage ratios at 2.1x at the end of Q3 2025
(Remains within the low end of 15-year historical range)

STOCK REPURCHASES

Reinitiated stock repurchases in 2024 with an initial goal to **offset annual equity award dilution**

~$450M repurchased in 2024-2025

M&A AND STRATEGIC PARTNERSHIPS

Remains a long-term priority and **enhances growth strategy**

Invested >$4.5B in >25 acquisitions since 2012**

*LTM 2025 based on LTM (last twelve months) financial information through September 27, 2025.
** Acquisition statistics do not include planned KF or PathoQuest acquisitions since transactions have not yet closed.

CRL's Evolutionary Approach to NAMs & Animal Alternatives

CRL is committed to remaining the leader in preclinical drug development solutions

- CRL has a well-established commitment to and track record for **replacement, reduction, and refinement (3Rs)** of ethical animal use for biomedical research, and has supported FDA's efforts – and NIH's – to advance validation and adoption of **new approach methodologies (or NAMs)** over many years
- We have recognized this trajectory of science and technology, and in April 2024, formalized our own **Alternative Methods Advancement Project (or AMAP initiative)** dedicated to advancing development of alternatives to reduce animal testing
- In 2025, CRL launched our NAMs strategy and **Scientific Advisory Board (SAB)**
  - **Former FDA Principal Deputy Commissioner Dr. Namandjé Bumpus** is leading the SAB and has **joined CRL as SVP, Chief Scientific and Innovation Officer**
  - Initial focus areas of SAB include: virtual control groups (VCGs) for safety assessment studies, *in vitro* skin sensitization assays, and *in vitro* immunogenicity assays
- FDA has focused initial NAMs roadmap on **monoclonal antibodies (mAbs)**, specifically to reduce the duration of chronic NHP studies
  - FDA recently issued draft guidance on chronic mAbs studies after already waiving certain long-term NHP studies for mAbs for many years
    - mAbs generally show less toxicity than small molecule drugs and are a lower risk and more predictable modality
    - Certain mAbs have no relevant research models to use in safety testing

CRL's NAMs Capabilities and Current State of Industry Application

CRL generated ~$200M in annual DSA revenue from NAMs, with majority in discovery

Established applications

Frequently used today in preclinical workflows:

- D **Human disease-relevant cell models:** replaces early animal models used to validate target-disease linkages
- D ***In silico* ADME modeling:** computational modeling to predict how drugs behave in the body
- S ***In vitro* genotoxicity:** assays such as Ames bacterial reverse mutation test that assess DNA damage potential *in vitro*
- D ***In silico* predictive safety modeling:** computational QSAR models for predicting drug toxicity
- D S **Physiologically based pharmacokinetic modeling:** PBPK simulations to predict pharmaco-kinetics and drug-drug interactions

Emerging opportunities

In advanced validation or early adoption, with clear tailwinds and pilot deployments:

- D S **Organ-on-chip:** Microfluidic devices lined with human cells designed to model early efficacy and organ toxicity (e.g., liver, kidney) *in vitro*
- D S **Organoids based models:** 3D tissue cultures derived from human cells used to model diseases and improve target validation & efficacy screening
- D S ***In silico* AI/ML models:** predictive AI models to predict drug toxicity and efficacy

Future exploratory use-cases

Disruptive concepts not standard but being explored:

- D S **Whole-body-on-a-chip:** Full body human micro-physiological system (MPS) for PK/PD and systemic tox
- D S **AI-based virtual human trial simulations:** Advanced *in silico* platforms that simulate systemic drug effects across virtual populations

Application	D	= Discovery	S	= Safety
CRL activity level	●	= Active	○	= Nascent

Note: Represents a non-exhaustive list of CRL and industry NAMs capabilities.

charles river

Recent DSA Biopharma Demand Trends

Biotech demand environment beginning to improve and global biopharma demand stabilized in 2025

- Following slower summer months, **biotech demand trends improved throughout 2H25**
  - Led to continued monthly improvement in 2H25 DSA demand KPIs
  - Driven by improved biotech funding in 2H25, including **4Q25 that was the highest funding quarter on record (surpassing 1Q21)**
- **Global biopharma demand** appeared to have bottomed and **began to improve** in early 2025 despite drug pricing and pharma tariff policy concerns
- Overall, pharma R&D budgets have stabilized and expected to remain at more **normalized levels** of growth for the **next several years**
  - However, DSA revenue from global biopharma clients rebounded and **increased in 3Q25**

Biotech Funding Trends*



*Source: Jefferies December 2025 biotech funding update; 2025 Commercial IND Applications estimated based on Sept. 2025 YTD run rate, CDER Commercial IND Applications, Pitchbook

charles river

Recent Demand Trends and Preliminary 2026 Outlook

- **Q4 DSA Trends:** DSA demand trends continued to improve throughout 2H25, resulting in **preliminary DSA net book-to-bill of ~1.1x in 4Q25**
  - Improving trends during 2H25 were primarily driven by **small and mid-sized biotech clients**, while **global biopharma** net bookings also increased in 4Q25
- **2026 Revenue:** Expect top end of 2026 guidance ranges for **organic revenue growth will be at least flat** for both consolidated outlook and for the DSA segment
  - Cautiously optimistic that favorable DSA demand KPIs will continue into 2026, resulting in **return to revenue growth in 2H26**
  - Expected improvement in Manufacturing organic revenue growth rate will be offset by anticipated RMS headwinds from timing of NHP shipments and CRADL™ occupancy
  - Foreign exchange (FX) expected to be an incremental benefit of 100-150 bps to reported revenue growth in 2026
- **2026 Non-GAAP Operating Margin**: Incremental cost savings in 2026 totaling **>$100M** will help to offset annual cost inflation until revenue growth reinvigorates
  - This outlook **does not yet reflect potential impact of K.F. and PathoQuest acquisitions or planned divestitures**, which would collectively benefit the non-GAAP operating margin once the transactions are completed
- Plan to issue **2026 guidance** when we report 4Q25/FY25 financial results in **February**

CEO Succession Plan

Comprehensive, Board-led succession process designed to ensure long-term continuity, stability, and strategic alignment

- On January 8th, **Chair, President & CEO Jim Foster** announced his **plans to retire on May 5th** at the conclusion of the 2026 Annual Meeting of Shareholders
  - Mr. Foster will remain a **non-executive Director** after 2026 Annual Meeting
  - Mr. Foster has had a 50-year career at CRL, including **>30 years as CEO**
- Board unanimously appointed current Executive VP & COO **Birgit Girshick as the next CEO** in May
  - Ms. Girshick also nominated by the Board to be a **Director** effective at the 2026 Annual Meeting
  - Ms. Girshick has had >35 year career at CRL, including **nearly 5 years as COO**
- **Dr. Martin Mackay**, current Lead Independent Director, will become **Chair** at the conclusion of the 2026 Annual Meeting
  - Separation of Chair and CEO roles at CRL to align with **best practices for corporate governance** and oversight, including a non-executive, independent Chairperson

Laser Focused on Advancing our Strategic Imperatives

Strengthen Portfolio

Identified areas of future growth that align with core competencies
- Focusing on science and innovative solutions in the areas of **bioanalysis**, ***in vitro*** **services** including **NAMs**, and strengthening **geographic presence**

Enhance Speed & Efficiency

Driving a client-centric culture focused on "best-in class" quality, client service, and speed
- Maximizing synergies across portfolio to drive value for clients through process optimization/ harmonization and to further reduce our clients' drug development timelines

Creating a more scalable footprint and efficient operating model to drive profitable growth

Champion Technology

Transforming industry and client experience with best-in-class technology platform and partnerships
- Real-time access to scientific data with self-service options, including through Apollo™
- **E-commerce** solutions and **AI/machine learning**

Laser Focused on Advancing our Strategic Imperatives, cont.

Promote Innovation

Remain at leading edge of science by leveraging our proven and efficient technologies for drug discovery and preclinical development

- Strategy includes investing in **advanced modalities**, **alternative technologies** (i.e. AI / biosimulation), and **NAMs** (non-animal methodologies) to drive innovation and reduce animal use

Advance Culture

Delivering meaningful contributions through a purpose-driven work environment

- Continuing to build on strong culture, focus on well-being, **connection to a purpose**, and provide opportunities for growth

charles river

Regulation G
Financial Reconciliations

CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
RECONCILIATION OF LAST TWELVE MONTHS (LTM) REVENUE & NON-GAAP OPERATING INCOME (1)
(dollars in thousands)

Revenue	**RMS**	**DSA**	**Manufacturing**	**Total CRL**
Fiscal Year Ended December 28, 2024	$829,377	$2,451,280	$769,332	$4,049,989
Nine Months Ended September 27, 2025	639,818	1,811,323	570,014	3,021,155
Less: Nine Months Ended September 28, 2024	(625,120)	(1,847,931)	(574,389)	(3,047,440)
Last Twelve Months (LTM) Ended September 27, 2025	**$844,075**	**$2,414,672**	**$764,957**	**$4,023,704**
Segment % of Total	*20.98%*	*60.01%*	*19.01%*	*100%*

Non-GAAP Operating Income (2)	**RMS**	**DSA**	**Manufacturing**	**Unallocated Corp.**	**Total CRL**
Fiscal Year Ended December 28, 2024	$196,825	$629,984	$210,432	($231,297)	$805,944
Nine Months Ended September 27, 2025	164,891	463,399	157,832	(171,979)	614,143
Less: Nine Months Ended September 28, 2024	(150,286)	(481,005)	(154,526)	179,401	(606,416)
Last Twelve Months (LTM) Ended September 27, 2025	**$211,430**	**$612,378**	**$213,738**	**($223,875)**	**$813,671**
LTM 2025 Operating Margin %	***25.0%***	***25.4%***	***27.9%***		***20.2%***

Non-GAAP Net Income	**Total CRL**
Fiscal Year Ended December 28, 2024	$532,903
Nine Months Ended September 27, 2025	393,445
Less: Nine Months Ended September 28, 2024	(396,294)
Last Twelve Months (LTM) Ended September 27, 2025	**$530,054**

Non-GAAP Earnings Per Share	
Weighted average shares outstanding - Diluted	50,239
Last Twelve Months (LTM) Ended September 27, 2025	**$10.55**

Free Cash Flow	**Operating CF**	**Cap Ex**	**Total CRL**
Fiscal Year Ended December 28, 2024	$734,577	$232,967	$501,610
Nine Months Ended September 27, 2025	590,126	130,202	459,924
Less: Nine Months Ended September 28, 2024	(575,215)	(157,351)	(417,864)
Last Twelve Months (LTM) Ended September 27, 2025	**$749,488**	**$205,818**	**$543,670**

(1) Charles River management believes that supplementary non-GAAP financial measures provide useful information to allow investors to gain a meaningful understanding of our core operating results and future prospects, without the effect of often one-time charges and other items which are outside our normal operations, consistent with the manner in which management measures and forecasts the Company's performance. The supplementary non-GAAP financial measures included are not meant to be considered superior to, or a substitute for results of operations prepared in accordance with U.S. GAAP. The Company intends to continue to assess the potential value of reporting non-GAAP results consistent with applicable rules, regulations and guidance.

(2) See Financial Reconciliations section of the Company's Investor Relations web site at ir.criver.com for a reconciliation of GAAP to Non-GAAP Operating Income for each period.

charles river

CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
RECONCILIATION OF GAAP REVENUE GROWTH
TO NON-GAAP REVENUE GROWTH, ORGANIC (UNAUDITED) [1]

Twelve Months Ended September 27, 2025	Total CRL	RMS Segment	DSA Segment	MS Segment
Revenue growth, reported	(0.9)%	2.8 %	(2.4)%	(0.2)%
Increase due to foreign exchange	(0.4)%	(0.3)%	(0.3)%	(0.4)%
Impact of divestitures [2]	0.1 %	- %	0.1 %	- %
Non-GAAP revenue growth, organic [3]	**(1.2)%**	**2.5 %**	**(2.6)%**	**(0.6)%**

(1) Charles River management believes that supplementary non-GAAP financial measures provide useful information to allow investors to gain a meaningful understanding of our core operating results and future prospects, without the effect of often-one-time charges and other items which are outside our normal operations, consistent with the manner in which management measures and forecasts the Company's performance. The supplementary non-GAAP financial measures included are not meant to be considered superior to, or a substitute for results of operations prepared in accordance with U.S. GAAP. The Company intends to continue to assess the potential value of reporting non-GAAP results consistent with applicable rules, regulations and guidance.

(2) Impact of divestitures relates to the sale of a site within our Safety Assessment business.

(3) Organic revenue growth is defined as reported revenue growth adjusted for acquisitions, divestitures, and foreign exchange.

CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
RECONCILIATION OF GAAP EARNINGS TO NON-GAAP OPERATING INCOME [1]
(dollars in thousands)

	Twelve Months Ended			
	December 28, 2024	December 30, 2023	December 31, 2022	December 25, 2021
Revenue	$ 4,049,989	$ 4,129,409	$ 3,976,060	$ 3,540,160
Operating income	227,347	617,261	650,975	589,862
Operating income as a % of revenue	5.6 %	14.9 %	16.4 %	16.7 %
Add back:				
Amortization related to acquisitions [2]	171,542	139,592	146,934	128,148
Acquisition and integration-related adjustments [3]	34,841	24,070	18,566	15,867
Severance	54,186	11,611	4,088	4,718
Goodwill impairment [4]	215,000	—	—	—
Site consolidation and impairment charges	53,380	30,659	4,047	2,177
Third-party legal costs and certain related items [5]	49,648	15,620	9,358	1,291
Total non-GAAP adjustments to operating income	$ 578,597	$ 221,552	$ 182,993	$ 152,201
Operating income, excluding non-GAAP adjustments	$ 805,944	$ 838,813	$ 833,968	$ 742,063
Non-GAAP operating income as a % of revenue	19.9 %	20.3 %	21.0 %	21.0 %

(1) Charles River management believes that supplementary non-GAAP financial measures provide useful information to allow investors to gain a meaningful understanding of our core operating results and future prospects, without the effect of often-one-time charges and other items which are outside our normal operations, consistent with the manner in which management measures and forecasts the Company's performance. The supplementary non-GAAP financial measures included are not meant to be considered superior to, or a substitute for results of operations prepared in accordance with U.S. GAAP. The Company intends to continue to assess the potential value of reporting non-GAAP results consistent with applicable rules, regulations and guidance.

(2) Amortization related to acquisitions includes $9.4 million of accelerated amortization of certain client relationships in the Biologics Solutions reporting unit within the Manufacturing Solutions segment. The remaining value of this client relationship is $75.9 million and will be amortized over the remaining useful life of approximately 6 months in fiscal year 2025.

(3) These adjustments are related to the evaluation and integration of acquisitions, which primarily include transaction, third-party integration, and certain compensation costs, fair value adjustments associated with contingent consideration arrangements, and an adjustment related to certain indirect tax liabilities.

(4) In December 2024, a triggering event was identified for the Biologics Solutions reporting unit from a loss of key customers, ultimately resulting in a reduction in Biologics Solutions' long range financial outlook. As a result, the Company recognized a goodwill impairment charge of $215.0 million.

(5) Third-party legal costs are related to (a) an environmental litigation related to the Microbial Solutions business, which concluded in 2023 and (b) investigations by the U.S. government into the NHP supply chain applicable to our DSA business. Additionally within DSA, a $27 million inventory charge was incurred to write down inventory associated with the Cambodia-sourced non-human primate matter from February 16, 2023.

CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
RECONCILIATION OF GAAP EARNINGS TO NON-GAAP EARNINGS (UNAUDITED)[1]
(in thousands, except per share data)

	Twelve Months Ended			
	December 28, 2024	December 30, 2023	December 31, 2022	December 25, 2021
Net income attributable to common shareholders	$ 10,297	$ 474,624	$ 486,226	$ 390,982
Add back:				
Amortization related to acquisitions [2]	171,542	139,592	146,934	128,148
Acquisition and integration-related adjustments [3]	34,841	24,070	18,566	15,867
Severance	54,186	11,611	4,088	4,718
Goodwill impairment [4]	215,000	—	—	—
Site consolidation and impairment charges	53,380	30,659	4,047	2,177
Third-party legal costs and certain related items [5]	49,648	15,620	9,358	1,291
Write-off of deferred financing costs and fees related to debt financing	—	—	—	26,089
Incremental dividends attributable to noncontrolling interest holders [6]	11,906	—	—	—
Venture capital and strategic equity investment losses (gains), net	12,519	(93,515)	26,775	30,419
Gain on divestitures [7]	658	961	(123,524)	(22,656)
Other [8]	(3,273)	1,372	5,285	(2,942)
Tax effect of non-GAAP adjustments:				
Tax effect from enacted tax law changes	3,826	—	(382)	10,036
Non-cash tax provision (benefit) related to international financing structure [9]	1,818	4,694	4,648	4,809
Tax effect of the remaining non-GAAP adjustments	(83,445)	(60,789)	(11,399)	(58,404)
Net income attributable to common shareholders, excluding non-GAAP adjustments	$ 532,903	$ 548,899	$ 570,622	$ 530,534
Weighted average shares outstanding - Basic	51,380	51,227	50,812	50,293
Effect of dilutive securities:				
Stock options, restricted stock units and performance share units	248	224	489	1,132
Weighted average shares outstanding - Diluted	51,628	51,451	51,301	51,425
Earnings per share attributable to common shareholders:				
Basic	$ 0.20	$ 9.27	$ 9.57	$ 7.77
Diluted	$ 0.20	$ 9.22	$ 9.48	$ 7.60
Basic, excluding non-GAAP adjustments	$ 10.37	$ 10.72	$ 11.23	$ 10.55
Diluted, excluding non-GAAP adjustments	$ 10.32	$ 10.67	$ 11.12	$ 10.32

(1) Charles River management believes that supplementary non-GAAP financial measures provide useful information to allow investors to gain a meaningful understanding of our core operating results and future prospects, without the effect of often-one-time charges and other items which are outside our normal operations, consistent with the manner in which management measures and forecasts the Company's performance. The supplementary non-GAAP financial measures included are not meant to be considered superior to, or a substitute for results of operations prepared in accordance with U.S. GAAP. The Company intends to continue to assess the potential value of reporting non-GAAP results consistent with applicable rules, regulations and guidance.

(2) Amortization related to acquisitions includes $9.4 million of accelerated amortization of certain client relationships in the Biologics Solutions reporting unit within the Manufacturing Solutions segment. The remaining value of this client relationship is $75.9 million and will be amortized over the remaining useful life of approximately 6 months in fiscal year 2025.

(3) These adjustments are related to the evaluation and integration of acquisitions, which primarily include transaction, third-party integration, and certain compensation costs, and fair value adjustments associated with contingent consideration arrangements, and an adjustment related to certain indirect tax liabilities.

(4) In December 2024, a triggering event was identified for the Biologics Solutions reporting unit from a loss of key customers, ultimately resulting in a reduction in Biologics Solutions' long range financial outlook. As a result, the Company recognized a goodwill impairment charge of $215.0 million.

(5) Third-party legal costs are related to (a) an environmental litigation related to the Microbial Solutions business, which concluded in 2023 and (b) investigations by the U.S. government into the NHP supply chain applicable to our DSA business. Additionally within DSA, a $27 million inventory charge was incurred to write down inventory associated with the Cambodia-sourced non-human primate matter from February 16, 2023.

(6) This amount represents incremental declared and undeclared dividends attributable to Noveprim noncontrolling interest holders who receive preferential dividends for fiscal year 2024.

(7) The amount included in 2024 relates to a loss on the sale of a Safety Assessment site. Adjustments included in 2023 relate to the gain on sale of our Avian Vaccine business, which was divested in 2022. Adjustments included in 2022 relate to the gain on sale of our Avian business. Adjustments included in 2021 relate to the preliminary gain on sale of our RMS Japan business as well as a gain on an immaterial divestiture.

(8) Amounts included in 2024 relate to portion of non-GAAP adjustments associated with the Noveprim. Amounts included in 2023 relate to transfer taxes paid in connection with the Noveprim Group acquisition and a final adjustment on the termination of a Canadian pension plan. Adjustments included in 2022 primarily relate to a purchase price adjustment in connection with the 2021 divestiture of RMS Japan, a loss on the termination of a Canadian pension plan, and the reversal of an indemnification asset related to a prior acquisition. Adjustment included in 2021 relates to the finalization of an annuity purchase related to the termination of our U.S. pension plan.

(9) This adjustment relates to the recognition of deferred tax assets expected to be utilized as a result of changes to the Company's international financing structure.

charles river

CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
RECONCILIATION OF FREE CASH FLOW (NON-GAAP) [1]
(dollars in thousands)

	Twelve Months Ended			
	December 28, 2024	**December 30, 2023**	**December 31, 2022**	**December 25, 2021**
Net cash provided by operating activities	$ 734,577	$ 683,898	$ 619,640	$ 760,799
Add back: Tax impact of Avian divestiture [2]	—	—	35,344	—
Less: Capital expenditures	(232,967)	(318,528)	(324,733)	(228,772)
Free cash flow	$ 501,610	$ 365,370	$ 330,251	$ 532,027

[1] Charles River management believes that supplementary non-GAAP financial measures provide useful information to allow investors to gain a meaningful understanding of our core operating results and future prospects, without the effect of often-one-time charges and other items which are outside our normal operations, consistent with the manner in which management measures and forecasts the Company's performance. The supplementary non-GAAP financial measures included are not meant to be considered superior to, or a substitute for results of operations prepared in accordance with U.S. GAAP. The Company intends to continue to assess the potential value of reporting non-GAAP results consistent with applicable rules, regulations and guidance.

[2] Free cash flow has been adjusted to exclude the cash tax impact related to the divestiture of our Avian business, which is recorded in Net cash provided by operating activities, because divestitures are outside of our normal operations, the corresponding cash proceeds from the divestiture are reflected in Cash Flows relating to Investing Activities, and the impact of the Avian divestiture is large, which can adversely affect the comparability of our results on a period-to-period basis.

CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
RECONCILIATION OF GAAP TO NON-GAAP
SELECTED BUSINESS SEGMENT INFORMATION (UNAUDITED)[1]
(in thousands, except percentages)

	Three Months Ended		Nine Months Ended	
	September 27, 2025	September 28, 2024	September 27, 2025	September 28, 2024
Research Models and Services				
Revenue	$ 213,474	$ 197,824	$ 639,818	$ 625,120
Operating income	34,553	27,544	113,944	100,641
Operating income as a % of revenue	16.2 %	13.9 %	17.8 %	16.1 %
Add back:				
Amortization related to acquisitions	12,905	9,086	36,266	26,731
Acquisition, integration, and divestiture-related adjustments [3]	—	—	14	337
Severance	136	2,651	3,664	3,685
Asset impairment	4,635	1,266	7,458	14,909
Site consolidation charges	1,053	1,052	3,545	3,983
Total non-GAAP adjustments to operating income	$ 18,729	$ 14,055	$ 50,947	$ 49,645
Operating income, excluding non-GAAP adjustments	$ 53,282	$ 41,599	$ 164,891	$ 150,286
Non-GAAP operating income as a % of revenue	25.0 %	21.0 %	25.8 %	24.0 %
Depreciation and amortization	$ 21,939	$ 18,389	$ 63,410	$ 53,050
Capital expenditures	$ 3,173	$ 7,186	$ 14,099	$ 36,543
Discovery and Safety Assessment				
Revenue	$ 600,685	$ 615,060	$ 1,811,323	$ 1,847,931
Operating income	123,153	126,436	339,886	379,651
Operating income as a % of revenue	20.5 %	20.6 %	18.8 %	20.5 %
Add back:				
Amortization related to acquisitions	19,198	19,818	55,581	58,712
Acquisition, integration, and divestiture-related adjustments [3]	2,407	1,714	4,755	7,497
Severance	(148)	12,550	5,068	20,463
Asset impairment	693	552	22,390	1,064
Site consolidation charges	3,985	772	10,690	2,604
Third-party legal and advisory costs and certain related items[4]	3,242	6,713	25,029	11,014
Total non-GAAP adjustments to operating income	$ 29,377	$ 42,119	$ 123,513	$ 101,354
Operating income, excluding non-GAAP adjustments	$ 152,530	$ 168,555	$ 463,399	$ 481,005
Non-GAAP operating income as a % of revenue	25.4 %	27.4 %	25.6 %	26.0 %
Depreciation and amortization	$ 44,001	$ 47,751	$ 128,660	$ 141,269
Capital expenditures	$ 25,709	$ 22,773	$ 78,730	$ 91,176
Manufacturing Solutions				
Revenue	$ 190,693	$ 196,879	$ 570,014	$ 574,389
Operating income	39,926	40,188	43,367	111,099
Operating income as a % of revenue	20.9 %	20.4 %	7.6 %	19.3 %
Add back:				
Amortization related to acquisitions [2]	8,265	10,802	100,675	32,363
Acquisition, integration, and divestiture-related adjustments [3]	—	143	—	1,386
Severance	1,281	4,892	3,102	8,086
Asset impairment	91	—	6,449	25
Site consolidation charges	1,263	502	4,239	1,567
Total non-GAAP adjustments to operating income	$ 10,900	$ 16,339	$ 114,465	$ 43,427
Operating income, excluding non-GAAP adjustments	$ 50,826	$ 56,527	$ 157,832	$ 154,526
Non-GAAP operating income as a % of revenue	26.7 %	28.7 %	27.7 %	26.9 %
Depreciation and amortization	$ 17,377	$ 20,298	$ 127,343	$ 60,176
Capital expenditures	$ 5,191	$ 8,735	$ 33,631	$ 28,180

CONTINUED ON NEXT SLIDE

charles river

CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
RECONCILIATION OF GAAP TO NON-GAAP
SELECTED BUSINESS SEGMENT INFORMATION (UNAUDITED)[1]
(in thousands, except percentages)

	Three Months Ended		Nine Months Ended	
	September 27, 2025	September 28, 2024	September 27, 2025	September 28, 2024
CONTINUED FROM PREVIOUS SLIDE				
Unallocated Corporate Overhead	$ (63,833)	$ (76,763)	$ (188,595)	$ (196,357)
Add back:				
Acquisition, integration, and divestiture-related adjustments [3]	772	4,082	3,663	7,719
Severance	3,527	6,443	5,103	9,237
Asset impairment	—	—	184	—
Site consolidation charges	767	—	1,436	—
Third-party legal and advisory costs [4]	(146)	—	6,230	—
Total non-GAAP adjustments to operating expense	$ 4,920	$ 10,525	$ 16,616	$ 16,956
Unallocated corporate overhead, excluding non-GAAP adjustments	$ (58,913)	$ (66,238)	$ (171,979)	$ (179,401)
Total				
Revenue	$ 1,004,852	$ 1,009,763	$ 3,021,155	$ 3,047,440
Operating income	133,799	117,405	308,602	395,034
Operating income as a % of revenue	13.3 %	11.6 %	10.2 %	13.0 %
Add back:				
Amortization related to acquisitions [2]	40,368	39,706	192,522	117,806
Acquisition, integration, and divestiture-related adjustments [3]	3,179	5,939	8,432	16,939
Severance	4,796	26,536	16,937	41,471
Asset impairment	5,419	1,818	36,481	15,998
Site consolidation charges	7,068	2,326	19,910	8,154
Third-party legal and advisory costs and certain related items [4]	3,096	6,713	31,259	11,014
Total non-GAAP adjustments to operating income	$ 63,926	$ 83,038	$ 305,541	$ 211,382
Operating income, excluding non-GAAP adjustments	$ 197,725	$ 200,443	$ 614,143	$ 606,416
Non-GAAP operating income as a % of revenue	19.7 %	19.9 %	20.3 %	19.9 %
Depreciation and amortization	$ 85,164	$ 88,198	$ 325,035	$ 259,637
Capital expenditures	$ 35,580	$ 38,721	$ 130,202	$ 157,351

(1) Charles River management believes that supplementary non-GAAP financial measures provide useful information to allow investors to gain a meaningful understanding of our core operating results and future prospects, without the effect of often-one-time charges and other items which are outside our normal operations, consistent with the manner in which management measures and forecasts the Company's performance. The supplementary non-GAAP financial measures included are not meant to be considered superior to, or a substitute for results of operations prepared in accordance with U.S. GAAP. The Company intends to continue to assess the potential value of reporting non-GAAP results consistent with applicable rules, regulations and guidance.

(2) Amortization related to acquisitions for the nine months ended September 27, 2025 includes $71.0 million of accelerated amortization of certain client relationships in the Biologics Solutions reporting unit within the Manufacturing Solutions segment.

(3) These adjustments are related to the evaluation and integration of acquisitions and divestitures, and primarily include transaction, advisory, certain third-party integration, certain compensation costs, and related costs; as well as fair value adjustments associated with contingent consideration arrangements.

(4) Third-party legal and advisory costs incurred within Unallocated Corporate are associated with the execution of the Cooperation Agreement with a shareholder. Within our DSA business, third-party legal costs incurred are associated with investigations by the U.S. government into the NHP supply chain. Additionally included within DSA, due to the utilization of NHPs, are reductions to the previous $27 million inventory charge incurred during fiscal 2024, to write down inventory associated with the Cambodia-sourced non-human primate matter from February 16, 2023, as a result of the cases being closed during fiscal 2025.

CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
RECONCILIATION OF GAAP EARNINGS TO NON-GAAP EARNINGS (UNAUDITED)[1]
(in thousands, except per share data)

	Three Months Ended		Nine Months Ended	
	September 27, 2025	September 28, 2024	September 27, 2025	September 28, 2024
Net income available to Charles River Laboratories International, Inc. common shareholders	$ 54,422	$ 68,679	$ 132,217	$ 225,996
Add back:				
Adjustment of redeemable noncontrolling interest [2]	—	379	—	1,081
Incremental dividends attributable to noncontrolling interest holders [3]	—	599	—	9,621
Non-GAAP adjustments to operating income [4]	62,632	82,315	302,104	209,332
Venture capital and strategic equity investment (gains) losses and impairments, net	20,201	(2,507)	31,594	(9,171)
(Gain) loss on divestitures [5]	—	—	(3,376)	658
Tax effect of non-GAAP adjustments:				
Non-cash tax provision related to international financing structure [6]	—	292	—	1,504
Enacted tax law changes	3,236	3,596	3,236	3,596
Tax effect of the remaining non-GAAP adjustments	(20,148)	(19,608)	(72,330)	(46,323)
Net income available to Charles River Laboratories International, Inc. common shareholders, excluding non-GAAP adjustments	$ 120,343	$ 133,745	$ 393,445	$ 396,294
Weighted average shares outstanding - Basic	49,213	51,394	49,680	51,461
Effect of dilutive securities:				
Stock options, restricted stock units and performance share units	213	189	186	252
Weighted average shares outstanding - Diluted	49,426	51,583	49,866	51,713
Earnings per share attributable to common shareholders:				
Basic	$ 1.11	$ 1.34	$ 2.66	$ 4.39
Diluted	$ 1.10	$ 1.33	$ 2.65	$ 4.37
Basic, excluding non-GAAP adjustments	$ 2.45	$ 2.60	$ 7.92	$ 7.70
Diluted, excluding non-GAAP adjustments	$ 2.43	$ 2.59	$ 7.89	$ 7.66

(1) Charles River management believes that supplementary non-GAAP financial measures provide useful information to allow investors to gain a meaningful understanding of our core operating results and future prospects, without the effect of often-one-time charges and other items which are outside our normal operations, consistent with the manner in which management measures and forecasts the Company's performance. The supplementary non-GAAP financial measures included are not meant to be considered superior to, or a substitute for results of operations prepared in accordance with U.S. GAAP. The Company intends to continue to assess the potential value of reporting non-GAAP results consistent with applicable rules, regulations and guidance.

(2) This amount represents accretion adjustments of the Noveprim redeemable noncontrolling interest.

(3) This amount represents incremental declared dividends attributable to Noveprim noncontrolling interest holders who receive preferential dividends for fiscal year 2024.

(4) This amount excludes non-GAAP adjustments attributable to noncontrolling interest holders.

(5) The amount included in 2025 relates to a gain on the sale of a DSA site while the amount included in 2024 relates to a loss on the sale of a DSA site.

(6) This amount relates to the recognition of deferred tax assets expected to be utilized as a result of changes to the Company's international financing structure.

charles river

CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
RECONCILIATION OF FREE CASH FLOW (NON-GAAP) (UNAUDITED)[1]
(in thousands)

	Three Months Ended		Nine Months Ended	
	September 27, 2025	**September 28, 2024**	**September 27, 2025**	**September 28, 2024**
Net cash provided by operating activities	$ 213,826	$ 251,792	$ 590,126	$ 575,215
Less: Capital expenditures	(35,580)	(38,721)	(130,202)	(157,351)
Free cash flow	$ 178,246	$ 213,071	$ 459,924	$ 417,864

(1) Charles River management believes that supplementary non-GAAP financial measures provide useful information to allow investors to gain a meaningful understanding of our core operating results and future prospects, without the effect of often-one-time charges and other items which are outside our normal operations, consistent with the manner in which management measures and forecasts the Company's performance. The supplementary non-GAAP financial measures included are not meant to be considered superior to, or a substitute for results of operations prepared in accordance with U.S. GAAP. The Company intends to continue to assess the potential value of reporting non-GAAP results consistent with applicable rules, regulations and guidance.

charles river

CRL
LISTED
NYSE